Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CERO CERo Therapeutics	$8.73 +0.3%	$9.81	$6.71 ▼ $895.40	$3.37M	0.48	314,819 shs	46,992 shs
GLMD Galmed Pharmaceuticals	$1.83 -21.5%	$1.66	$1.15 ▼ $23.80	$3.03M	0.6	1.35 million shs	1.14 million shs
ONVO Organovo		$3.94	$1.56 ▼ $21.96	$3.47M	1.13	617,505 shs	243,634 shs
TRVN Trevena	$0.91	$1.06	$0.73 ▼ $7.85	$873K	0.61	2,072 shs	8 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CERO CERo Therapeutics	0.00%	+0.11%	-24.09%	-29.25%	-97.89%
GLMD Galmed Pharmaceuticals	0.00%	-5.18%	+2.81%	+32.61%	-52.19%
ONVO Organovo	0.00%	0.00%	0.00%	+18.60%	-71.06%
TRVN Trevena	0.00%	-2.69%	-20.18%	-18.75%	-84.98%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CERO CERo Therapeutics	3.0527 of 5 stars	3.7	4.0	0.0	0.0	0.0	0.8	0.0
GLMD Galmed Pharmaceuticals	0.707 of 5 stars	0.0	3.0	0.0	0.0	0.6	2.5	0.6
ONVO Organovo	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TRVN Trevena	1.24 of 5 stars	3.0	3.0	0.0	0.0	0.0	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CERO CERo Therapeutics	3.33	Buy	$45.00	415.46% Upside
GLMD Galmed Pharmaceuticals	2.00	Hold	N/A	N/A
ONVO Organovo	0.00	N/A	N/A	N/A
TRVN Trevena	2.00	Hold	$5.00	449.45% Upside

Current Analyst Ratings Breakdown

Latest TRVN, ONVO, GLMD, and CERO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/23/2025	CERO CERo Therapeutics	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
6/23/2025	CERO CERo Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$30.00
5/30/2025	CERO CERo Therapeutics	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/30/2025	CERO CERo Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/19/2025	CERO CERo Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
4/22/2025	CERO CERo Therapeutics	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/22/2025	CERO CERo Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$220.00 ➝ $220.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CERO CERo Therapeutics	N/A	N/A	N/A	N/A	($41.98) per share	N/A
GLMD Galmed Pharmaceuticals	N/A	N/A	N/A	N/A	$9.87 per share	N/A
ONVO Organovo	$122K	0.00	N/A	N/A	$0.02 per share	0.00
TRVN Trevena	$443K	1.97	N/A	N/A	($11.07) per share	-0.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CERO CERo Therapeutics	-$8.30M	N/A	0.00	∞	N/A	N/A	N/A	-199.71%	8/13/2025 (Estimated)
GLMD Galmed Pharmaceuticals	-$7.52M	-$16.66	N/A	∞	N/A	N/A	-32.21%	-28.59%	8/27/2025 (Estimated)
ONVO Organovo	-$14.67M	-$10.20	N/A	N/A	N/A	-10,151.64%	-346.26%	-187.53%	N/A
TRVN Trevena	-$40.29M	-$47.04	N/A	N/A	N/A	N/A	N/A	-119.55%	8/6/2025 (Estimated)

Latest TRVN, ONVO, GLMD, and CERO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/22/2025	Q1 2025	GLMD Galmed Pharmaceuticals	N/A	-$0.62	N/A	-$0.62	N/A	N/A
5/15/2025	N/A	CERO CERo Therapeutics	N/A	-$31.80	N/A	-$1.59	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CERO CERo Therapeutics	N/A	N/A	N/A	N/A	N/A
GLMD Galmed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ONVO Organovo	N/A	N/A	N/A	N/A	N/A
TRVN Trevena	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CERO CERo Therapeutics	N/A	0.73	0.73
GLMD Galmed Pharmaceuticals	N/A	9.02	9.02
ONVO Organovo	N/A	0.72	1.72
TRVN Trevena	N/A	2.42	2.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CERO CERo Therapeutics	29.64%
GLMD Galmed Pharmaceuticals	76.14%
ONVO Organovo	8.23%
TRVN Trevena	13.56%

Insider Ownership

Company	Insider Ownership
CERO CERo Therapeutics	12.72%
GLMD Galmed Pharmaceuticals	19.80%
ONVO Organovo	3.72%
TRVN Trevena	2.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CERO CERo Therapeutics	8	386,000	337,000	N/A
GLMD Galmed Pharmaceuticals	20	1.65 million	1.33 million	Not Optionable
ONVO Organovo	20	1.70 million	14.79 million	Optionable
TRVN Trevena	40	959,000	841,000	Optionable

TRVN, ONVO, GLMD, and CERO Headlines

Recent News About These Companies

Softball: Conrad Weiser’s Alex Trevena earns statewide player of the year award; 5 other Berks players honored

July 8, 2025 | msn.com

Trevena, Inc. (TRVN) - Yahoo Finance

June 29, 2025 | finance.yahoo.com

Trevena Enters Securities Exchange Agreement with Investor

May 15, 2025 | tipranks.com

Berks sports roundup: Alex Trevena helps Conrad Weiser to 8-5 softball win

April 11, 2025 | readingeagle.comR

Vanessa Hudgens and Oliver Trevena Appear at Expo West for Caliwater

March 9, 2025 | msn.com

JMP Securities downgrades Trevena (TRVN) to a Hold

December 27, 2024 | markets.businessinsider.com

‘Plane’ Actor Oliver Trevena Signs With Untitled Entertainment

December 16, 2024 | yahoo.com

Lyme Regis town councillor John Trevena stand down

December 11, 2024 | bridportnews.co.ukB

Trevena (TRVN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

December 10, 2024 | zacks.com

Trevena appoints new financial chief

November 29, 2024 | investing.com

Trevena Appoints Katrine Sutton as New CFO

November 27, 2024 | tipranks.com

HC Wainwright & Co. Downgrades Trevena (TRVN)

November 16, 2024 | msn.com

Trevena, Inc. Navigates Financial Challenges and Strategic Changes

November 9, 2024 | msn.com

Chester County biopharm firm's latest layoffs impact its C-suite

November 7, 2024 | bizjournals.com

Trevena teeters in dangerous territory, terminating CEO and other execs amid strategic review

November 7, 2024 | fiercebiotech.comF

Trevena Reports Third Quarter 2024 Results and Provides Business Update

November 7, 2024 | globenewswire.com

Why Trevena (TRVN) Stock Is Down 43% Today

October 8, 2024 | msn.com

Trevena, Inc. Faces Delisting from Nasdaq

October 6, 2024 | msn.com

Trevena Announces Receipt of Nasdaq Delisting Notification

October 4, 2024 | globenewswire.com

Learn to Evaluate (TRVN) using the Charts

September 16, 2024 | news.stocktradersdaily.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRVN, ONVO, GLMD, and CERO Company Descriptions

CERo Therapeutics NASDAQ:CERO

$8.73 +0.03 (+0.34%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$8.80 +0.06 (+0.74%)

As of 07/18/2025 07:54 PM Eastern

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

Galmed Pharmaceuticals NASDAQ:GLMD

$1.83 -0.50 (-21.46%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.90 +0.08 (+4.10%)

As of 07/18/2025 07:49 PM Eastern

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

Organovo NASDAQ:ONVO

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.

Trevena NASDAQ:TRVN

$0.91 0.00 (0.00%)

As of 07/18/2025

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time